在患有血液性恶性瘤的患者中Episil®的有效性:一项比较性研究
Taeko Fukutani1, Yukio Yoshioka2, Shinpei Imori3
1Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami Ward, Hiroshima, 734-8553, Japan. fukutani@hiroshima-u.ac.jp.
BMC oral health
|May 2, 2024
概括
在患有血液性恶性瘤的患者中,Episil®有效治疗口腔粘膜炎,提供疼痛缓解和功能改善. 这种医疗材料证明了在多个部位出现粘膜炎的患者的特殊益处.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 口腔医学是指口腔医学.
背景情况:
- 埃皮西尔 (Episil®) 是一种不可吸收的液体医疗材料,用于治疗口腔粘膜炎.
- 关于其在血液恶性瘤中使用的数据有限.
- 这项研究通过评估Episil®在特定的血液癌症中来弥补这一差距.
研究的目的:
- 评估Episil®在治疗口腔粘膜炎中的疗效.
- 评估其对疼痛,言语和食功能的影响.
- 为了研究其在急性骨髓性白血病,恶性淋巴瘤,急性淋巴细胞白血病,多发性骨髓瘤和骨髓质疏松综合征的患者中的有用性.
主要方法:
- 一项涉及37名患有血液性恶性瘤和口腔粘膜炎的患者的研究.
- 患者在广岛红十字会和原子弹手术医院接受了Episil®治疗.
- 使用客观 (CTCAE v3.0) 和主观 (原始评估协议) 措施来评估口腔粘膜炎的严重程度.
主要成果:
- 84%的参与者认为Episil®的感觉非常好或好.
- 粘膜炎的严重程度在19%的患者下降,特别是在多个受影响部位的患者中.
- 据报道,疼痛缓解,言语和食功能显著改善,特别是在3级粘膜炎中.
结论:
- 在患有血液性恶性瘤的患者中,Episil®在治疗口腔粘膜炎方面表现出有效性.
- 对于影响多个口腔部位的粘膜炎患者来说,它特别有益.
- 这种材料可以改善疼痛,语言和食功能,提高患者的生活质量.
相关概念视频
Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...


